[{"id":"ca1e75d4-24cd-4bf5-b1bc-b2590263f177","acronym":"","url":"https://clinicaltrials.gov/study/NCT01756118","created_at":"2021-01-17T17:42:08.990Z","updated_at":"2024-07-02T16:35:55.304Z","phase":"Phase 1","brief_title":"A Phase I, Dose-finding Study of BEZ235 in Adult Patients With Relapsed or Refractory Acute Leukemia","source_id_and_acronym":"NCT01756118","lead_sponsor":"Goethe University","biomarkers":" ABL1 • BCR","pipe":"","alterations":" ","tags":["ABL1 • BCR"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e dactolisib (RTB101) • sirolimus"],"overall_status":"Completed","enrollment":" Enrollment 24","initiation":"Initiation: 06/01/2012","start_date":" 06/01/2012","primary_txt":" Primary completion: 12/01/2017","primary_completion_date":" 12/01/2017","study_txt":" Completion: 02/07/2020","study_completion_date":" 02/07/2020","last_update_posted":"2023-02-16"},{"id":"1c51c34e-b0e4-4282-8dd9-55eb5e71d87e","acronym":"","url":"https://clinicaltrials.gov/study/NCT01285466","created_at":"2021-01-18T05:12:58.574Z","updated_at":"2024-07-02T16:36:37.611Z","phase":"Phase 1","brief_title":"A Trial of Oral BEZ235 and BKM120 in Combination With Paclitaxel With or Without Trastuzumab","source_id_and_acronym":"NCT01285466","lead_sponsor":"Novartis Pharmaceuticals","biomarkers":" HER-2","pipe":"","alterations":" ","tags":["HER-2"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Herceptin (trastuzumab) • paclitaxel • dactolisib (RTB101) • buparlisib (AN2025)"],"overall_status":"Completed","enrollment":" Enrollment 110","initiation":"Initiation: 01/01/2011","start_date":" 01/01/2011","primary_txt":" Primary completion: 10/01/2014","primary_completion_date":" 10/01/2014","study_txt":" Completion: 10/01/2014","study_completion_date":" 10/01/2014","last_update_posted":"2020-12-09"},{"id":"c209c616-da13-4965-9bf5-581dd8c2b372","acronym":"","url":"https://clinicaltrials.gov/study/NCT00620594","created_at":"2021-01-18T02:18:24.159Z","updated_at":"2024-07-02T16:36:37.600Z","phase":"Phase 1/2","brief_title":"A Phase I/II Study of BEZ235 in Patients With Advanced Solid Malignancies Enriched by Patients With Advanced Breast Cancer","source_id_and_acronym":"NCT00620594","lead_sponsor":"Novartis Pharmaceuticals","biomarkers":" EGFR • HER-2 • PIK3CA • PTEN","pipe":" | ","alterations":" EGFR mutation","tags":["EGFR • HER-2 • PIK3CA • PTEN"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e EGFR mutation"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e dactolisib (RTB101)"],"overall_status":"Completed","enrollment":" Enrollment 183","initiation":"Initiation: 12/21/2006","start_date":" 12/21/2006","primary_txt":" Primary completion: 01/08/2013","primary_completion_date":" 01/08/2013","study_txt":" Completion: 01/08/2013","study_completion_date":" 01/08/2013","last_update_posted":"2020-12-09"},{"id":"e0c05b75-c228-4f21-8d24-104f5616ad4c","acronym":"","url":"https://clinicaltrials.gov/study/NCT01471847","created_at":"2021-01-18T06:08:06.263Z","updated_at":"2024-07-02T16:36:37.593Z","phase":"Phase 1","brief_title":"A Phase Ib/II Study of BEZ235 and Trastuzumab in Patients With HER2-positive Breast Cancer Who Failed Prior to Trastuzumab","source_id_and_acronym":"NCT01471847","lead_sponsor":"Novartis Pharmaceuticals","biomarkers":" HER-2","pipe":" | ","alterations":" HER-2 positive","tags":["HER-2"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e HER-2 positive"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Herceptin (trastuzumab) • lapatinib • capecitabine • dactolisib (RTB101)"],"overall_status":"Completed","enrollment":" Enrollment 5","initiation":"Initiation: 02/01/2012","start_date":" 02/01/2012","primary_txt":" Primary completion: 06/01/2012","primary_completion_date":" 06/01/2012","study_txt":" Completion: 06/01/2012","study_completion_date":" 06/01/2012","last_update_posted":"2020-12-09"},{"id":"f7ef3a32-c39e-4a8b-ba39-902767a7f32b","acronym":"","url":"https://clinicaltrials.gov/study/NCT01195376","created_at":"2021-01-18T04:47:04.621Z","updated_at":"2024-07-02T16:36:37.555Z","phase":"Phase 1","brief_title":"A Study of BEZ235 in Adult Japanese Patients With Advanced Solid Tumors","source_id_and_acronym":"NCT01195376","lead_sponsor":"Novartis Pharmaceuticals","biomarkers":" PIK3CA • PTEN","pipe":" | ","alterations":" PIK3CA mutation • PTEN mutation • PTEN expression • PIK3CA mutation + PTEN mutation","tags":["PIK3CA • PTEN"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e PIK3CA mutation • PTEN mutation • PTEN expression • PIK3CA mutation + PTEN mutation"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e dactolisib (RTB101)"],"overall_status":"Completed","enrollment":" Enrollment 35","initiation":"Initiation: 10/01/2010","start_date":" 10/01/2010","primary_txt":" Primary completion: 07/01/2013","primary_completion_date":" 07/01/2013","study_txt":" Completion: 07/01/2013","study_completion_date":" 07/01/2013","last_update_posted":"2020-12-09"},{"id":"85cd9a9f-8c84-47eb-ab35-7124ea82be7d","acronym":"","url":"https://clinicaltrials.gov/study/NCT01337765","created_at":"2021-01-18T05:27:18.856Z","updated_at":"2024-07-02T16:36:40.180Z","phase":"Phase 1","brief_title":"Safety, Pharmacokinetics and Pharmacodynamics of BEZ235 Plus MEK162 in Selected Advanced Solid Tumor Patients","source_id_and_acronym":"NCT01337765","lead_sponsor":"Pfizer","biomarkers":" BRAF","pipe":"","alterations":" ","tags":["BRAF"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Mektovi (binimetinib) • dactolisib (RTB101)"],"overall_status":"Completed","enrollment":" Enrollment 29","initiation":"Initiation: 07/08/2011","start_date":" 07/08/2011","primary_txt":" Primary completion: 03/22/2013","primary_completion_date":" 03/22/2013","study_txt":" Completion: 03/22/2013","study_completion_date":" 03/22/2013","last_update_posted":"2020-10-09"},{"id":"df7469df-d5a6-4e7f-b8b4-2a16648bf852","acronym":"","url":"https://clinicaltrials.gov/study/NCT01248494","created_at":"2021-01-18T05:01:45.118Z","updated_at":"2024-07-02T16:37:30.275Z","phase":"Phase 1","brief_title":"PhIb BKM120 or BEZ235+Endocrine Treatment in Post-Menopausal Patients With Hormone Receptor + Metastatic Breast Cancer","source_id_and_acronym":"NCT01248494","lead_sponsor":"Vanderbilt-Ingram Cancer Center","biomarkers":" HER-2 • ER • PGR","pipe":" | ","alterations":" ER positive • HER-2 overexpression","tags":["HER-2 • ER • PGR"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e ER positive • HER-2 overexpression"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e dactolisib (RTB101) • letrozole • buparlisib (AN2025)"],"overall_status":"Completed","enrollment":" Enrollment 72","initiation":"Initiation: 11/01/2010","start_date":" 11/01/2010","primary_txt":" Primary completion: 12/01/2012","primary_completion_date":" 12/01/2012","study_txt":" Completion: 05/01/2016","study_completion_date":" 05/01/2016","last_update_posted":"2016-07-25"}]